Lifeway Foods Inc (LWAY)

$6.79 0.22 (3.35%)

18:12 EDT LWAY Stock Quote Delayed 30 Minutes

Volume:

Previous Close $6.79

Market Cap 107.81M

PE Ratio -264.92

EPS -0.02563

Volume (Avg. Vol.) 216,700

Day's Range 6.50 - 7.09

52-Week Range 1.43 - 8.89

Dividend & Yield N/A (N/A)

LWAY Stock Predictions, Articles, and Lifeway Foods Inc News

From the Web

Why One Analyst Thinks That Dell Is Undervalued

From Barron's Sep 19, 2020

Also, Wall Street views on Sirius XM, Equinix, Aaron’s, Vertex Pharmaceuticals, IMAX, and First Republic Bank.

Big Tech Weighs Too Much on the S&P 500. Feast on These Stocks Instead.

From Barron's Sep 18, 2020

The allure of Autodesk, Intuitive Surgical, PayPal, Vertex Pharmaceuticals, ServiceNow, and some small-cap funds. Also, Blackstone boss Steve Schwarzman’s take on the future of cities.

Top Biotech Stocks To Watch In Q4 2020

From StockMarket.com Sep 18, 2020

These Biotech Stocks Are At The Forefront of Medical Innovation.

European advisory group backs expanded use of Vertex's Kalydeco (NASDAQ:VRTX)

From Seeking Alpha Sep 18, 2020

The European Medicines Agency's advisory group CHMP has adopted a position opinion backing the use of Vertex Pharmaceuticals' (NASDAQ:VRTX) Kalydeco (ivacaftor) in children as young as four months old (previously six months old) with cystic fibrosis (CF) who have an R117H CFTR mutation or one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. It also backs its use in combination with tezacaftor in children as young as six years old (previously 12 years old) with CF who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the CFTR gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272 26A→G, and 3849+10kbC→T.A final decision from the European Commission usually takes ~60 days.

Stocks Are Heading Lower on September 10 Ahead of The ECB

From Talk Markets Sep 10, 2020

Stocks are trading lower this morning ahead of the ECB rate announcement.

Beyond Coronavirus: Moderna Teams Up With Vertex on Cystic Fibrosis Therapy

From The Motley Fool Sep 18, 2020

This is the companies' second project to tackle the lung disease.

Navellier Ratings

Powered by Portfolio Grader

Total Grade

A

Strong Buy